Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the molecular level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity. Encouraged by the clinical validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacological agents t...
Alternative Titles
Full title
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_70689187
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_70689187
Other Identifiers
ISSN
1552-4450
E-ISSN
1552-4469
DOI
10.1038/nchembio760
